BCR and acute lymphoblastic leukemia: Additionally, rituximab was administered depending on the treatment regimen: to patients with BCR::ABL1 negative B-precursor ALL and >20% CD20+ blasts (if treated according to the recommendations for elderly patients) as well as to all BCR::ABL1 negative and those BCR::ABL1 positive patients with >20% CD20+ blasts.